Cargando…
NMR Study of the Secondary Structure and Biopharmaceutical Formulation of an Active Branched Antimicrobial Peptide
The synthetic antimicrobial peptide SET-M33 is being developed as a possible new antibacterial candidate for the treatment of multi-drug resistant bacteria. SET-M33 is a branched peptide featuring higher resistance and bioavailability than its linear analogues. SET-M33 shows antimicrobial activity a...
Autores principales: | , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6930567/ https://www.ncbi.nlm.nih.gov/pubmed/31775296 http://dx.doi.org/10.3390/molecules24234290 |
_version_ | 1783482922100064256 |
---|---|
author | Castiglia, Francesca Zevolini, Fabrizia Riolo, Giulia Brunetti, Jlenia De Lazzari, Alessandra Moretto, Alberto Manetto, Giulia Fragai, Marco Algotsson, Jenny Evenäs, Johan Bracci, Luisa Pini, Alessandro Falciani, Chiara |
author_facet | Castiglia, Francesca Zevolini, Fabrizia Riolo, Giulia Brunetti, Jlenia De Lazzari, Alessandra Moretto, Alberto Manetto, Giulia Fragai, Marco Algotsson, Jenny Evenäs, Johan Bracci, Luisa Pini, Alessandro Falciani, Chiara |
author_sort | Castiglia, Francesca |
collection | PubMed |
description | The synthetic antimicrobial peptide SET-M33 is being developed as a possible new antibacterial candidate for the treatment of multi-drug resistant bacteria. SET-M33 is a branched peptide featuring higher resistance and bioavailability than its linear analogues. SET-M33 shows antimicrobial activity against different species of multi-resistant Gram-negative bacteria, including clinically isolated strains of Pseudomonas aeruginosa, Klebsiella pneumoniae, Acinetobacter baumanii and Escherichia coli. The secondary structure of this 40 amino acid peptide was investigated by NMR to fully characterize the product in the framework of preclinical studies. The possible presence of helixes or β-sheets in the structure had to be explored to predict the behavior of the branched peptide in solution, with a view to designing a formulation for parenteral administration. Since the final formulation of SET-M33 will be strictly defined in terms of counter-ions and additives, we also report the studies on a new salt form, SET-M33 chloride, that retains its activity against Gram-negative bacteria and gains in solubility, with a possible improvement in the pharmacokinetic profile. The opportunity of using a chloride counter-ion is very convenient from a process development point of view and did not increase the toxicity of the antimicrobial drug. |
format | Online Article Text |
id | pubmed-6930567 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-69305672019-12-26 NMR Study of the Secondary Structure and Biopharmaceutical Formulation of an Active Branched Antimicrobial Peptide Castiglia, Francesca Zevolini, Fabrizia Riolo, Giulia Brunetti, Jlenia De Lazzari, Alessandra Moretto, Alberto Manetto, Giulia Fragai, Marco Algotsson, Jenny Evenäs, Johan Bracci, Luisa Pini, Alessandro Falciani, Chiara Molecules Article The synthetic antimicrobial peptide SET-M33 is being developed as a possible new antibacterial candidate for the treatment of multi-drug resistant bacteria. SET-M33 is a branched peptide featuring higher resistance and bioavailability than its linear analogues. SET-M33 shows antimicrobial activity against different species of multi-resistant Gram-negative bacteria, including clinically isolated strains of Pseudomonas aeruginosa, Klebsiella pneumoniae, Acinetobacter baumanii and Escherichia coli. The secondary structure of this 40 amino acid peptide was investigated by NMR to fully characterize the product in the framework of preclinical studies. The possible presence of helixes or β-sheets in the structure had to be explored to predict the behavior of the branched peptide in solution, with a view to designing a formulation for parenteral administration. Since the final formulation of SET-M33 will be strictly defined in terms of counter-ions and additives, we also report the studies on a new salt form, SET-M33 chloride, that retains its activity against Gram-negative bacteria and gains in solubility, with a possible improvement in the pharmacokinetic profile. The opportunity of using a chloride counter-ion is very convenient from a process development point of view and did not increase the toxicity of the antimicrobial drug. MDPI 2019-11-25 /pmc/articles/PMC6930567/ /pubmed/31775296 http://dx.doi.org/10.3390/molecules24234290 Text en © 2019 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Castiglia, Francesca Zevolini, Fabrizia Riolo, Giulia Brunetti, Jlenia De Lazzari, Alessandra Moretto, Alberto Manetto, Giulia Fragai, Marco Algotsson, Jenny Evenäs, Johan Bracci, Luisa Pini, Alessandro Falciani, Chiara NMR Study of the Secondary Structure and Biopharmaceutical Formulation of an Active Branched Antimicrobial Peptide |
title | NMR Study of the Secondary Structure and Biopharmaceutical Formulation of an Active Branched Antimicrobial Peptide |
title_full | NMR Study of the Secondary Structure and Biopharmaceutical Formulation of an Active Branched Antimicrobial Peptide |
title_fullStr | NMR Study of the Secondary Structure and Biopharmaceutical Formulation of an Active Branched Antimicrobial Peptide |
title_full_unstemmed | NMR Study of the Secondary Structure and Biopharmaceutical Formulation of an Active Branched Antimicrobial Peptide |
title_short | NMR Study of the Secondary Structure and Biopharmaceutical Formulation of an Active Branched Antimicrobial Peptide |
title_sort | nmr study of the secondary structure and biopharmaceutical formulation of an active branched antimicrobial peptide |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6930567/ https://www.ncbi.nlm.nih.gov/pubmed/31775296 http://dx.doi.org/10.3390/molecules24234290 |
work_keys_str_mv | AT castigliafrancesca nmrstudyofthesecondarystructureandbiopharmaceuticalformulationofanactivebranchedantimicrobialpeptide AT zevolinifabrizia nmrstudyofthesecondarystructureandbiopharmaceuticalformulationofanactivebranchedantimicrobialpeptide AT riologiulia nmrstudyofthesecondarystructureandbiopharmaceuticalformulationofanactivebranchedantimicrobialpeptide AT brunettijlenia nmrstudyofthesecondarystructureandbiopharmaceuticalformulationofanactivebranchedantimicrobialpeptide AT delazzarialessandra nmrstudyofthesecondarystructureandbiopharmaceuticalformulationofanactivebranchedantimicrobialpeptide AT morettoalberto nmrstudyofthesecondarystructureandbiopharmaceuticalformulationofanactivebranchedantimicrobialpeptide AT manettogiulia nmrstudyofthesecondarystructureandbiopharmaceuticalformulationofanactivebranchedantimicrobialpeptide AT fragaimarco nmrstudyofthesecondarystructureandbiopharmaceuticalformulationofanactivebranchedantimicrobialpeptide AT algotssonjenny nmrstudyofthesecondarystructureandbiopharmaceuticalformulationofanactivebranchedantimicrobialpeptide AT evenasjohan nmrstudyofthesecondarystructureandbiopharmaceuticalformulationofanactivebranchedantimicrobialpeptide AT bracciluisa nmrstudyofthesecondarystructureandbiopharmaceuticalformulationofanactivebranchedantimicrobialpeptide AT pinialessandro nmrstudyofthesecondarystructureandbiopharmaceuticalformulationofanactivebranchedantimicrobialpeptide AT falcianichiara nmrstudyofthesecondarystructureandbiopharmaceuticalformulationofanactivebranchedantimicrobialpeptide |